Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangcao Tablet (唐草片) is a traditional Chinese medicine (TCM) formulation approved by the National Medical Products Administration (NMPA) of China. It is primarily used as an adjunct therapy for HIV/AIDS patients, with research and clinical use focused on alleviating side effects of highly active antiretroviral therapy (HAART), protecting against opportunistic infections, and increasing leukocyte counts in cases such as chemotherapy-induced leukopenia. The formulation contains a combination of herbal ingredients including common heron bill herb, mongolian milkvetch root, black nightshade herb, honeysuckle flower, common bombax flower, common terminalia fruit, spreading hedyotis herb, pomegranate bark, glutinousae rice root, water caltrop, mongolian snakegourd rind, Chinese thorowax root, Chinese mosla herb, suberect spatholobus stem, safflower, ginkgo leaf, purslane and others. Clinical studies indicate that Tangcao Tablet does not significantly affect the pharmacokinetics of lopinavir in HIV-infected patients[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tangcao tablet.